Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference

    AURORA, Ontario, Sept. 3 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: "HBP"
/ OTCQX: "HXBPF") today announced that John Docherty, president and chief
operating officer, will present at the Rodman and Renshaw 11th Annual
Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York
Palace Hotel in New York.  Mr. Docherty will provide an overview of the
Company's leading product development programs L-DOS47 and Topical Interferon
Alpha-2b.  The slide show portion of the presentation will be posted on the
Company's website, www.helixbiopharma.com, on September 9th, 2009.

    About Helix BioPharma Corp.
    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy.  The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies.  Helix's product development initiatives include its novel
L-DOS47 new drug candidate and its Topical Interferon Alpha-2b.  Helix is
listed on the TSX and FSE under the symbol "HBP" and on the OTCQX
International Market under the symbol "HXBPF".

    For further information contact:


    Investor & Media Relations
    Robert Flamm, Ph.D.                        Ian Stone
    Russo Partners LLC                         Russo Partners LLC
    Tel: (212) 845-4226                        Tel: (619) 814-3510
    Email: robert.flamm@russopartnersllc.com   Fax: (619) 955-5318
    www.russopartnersllc.com                   Email:

    This News Release contains certain forward-looking statements regarding
the Company's planned presentation at the Rodman & Renshaw 11th Annual
Healthcare Conference and the Company's research and development initiatives,
which statements can be identified by the use of forward looking terminology
such as "will", "developing", "September 9", or comparable terminology
referring to future events or results. Forward looking statements are
statements about the future and are inherently uncertain, and Helix's actual
results could differ materially from those anticipated in these
forward-looking statements as a result of numerous factors, including without
limitation, the fact that the Rodman & Renshaw presentation and the posting of
the slide show portion of the presentation on the Company's website are
subject to change or cancellation without notice; Helix's need for additional
future capital, which may not be available in a timely manner or at all;
uncertainty whether L-DOS47 or Topical Interferon Alpha-2b will be
successfully developed as a drug or otherwise commercialized; the need for
additional research and development, the outcome of which is uncertain; the
need for clinical trials, the occurrence and success of which cannot be
assured; product liability and insurance risks; the need for regulatory
approvals, which may not be obtained in a timely matter or at all;
intellectual property risks; manufacturing and upscaling risks; Helix's
dependence on numerous third parties, whose performance and interdependence
can critically affect the Company's performance; the effect of competition;
and the risk of changes in business strategy or development plans.  Such risks
and uncertainties, and others affecting the Company which could cause actual
results to vary materially from current results or those anticipated in
forward-looking statements and information, are more fully described in the
Company's latest Annual Information Form, MD&A and other reports filed with
the Canadian Securities Regulatory Authorities from time to time at
www.sedar.com, and in the Company's Form 20-F and other reports filed with the
U.S. S.E.C. from time to time (see www.sec.gov/edgar.shtml).  Forward-looking
statements and information are based on the beliefs, assumptions, opinions and
expectations of Helix's management at the time they are made, and Helix does
not assume any obligation to update any forward-looking statement or
information should those beliefs, assumptions, opinions or expectations
change, except as required by law.


For further information:

For further information: Investor & Media Relations, Robert Flamm,
Ph.D., +1-212-845-4226, robert.flamm@russopartnersllc.com, or Ian Stone,
+1-619-814-3510, Fax, +1-619-955-5318, ian.stone@russopartnersllc.com, both of
Russo Partners LLC Web Site: http://www.helixbiopharma.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890